Library · Metabolic & weight · Treatment of obesity and type 2 diabetes
Mazdutide (LY3305677 / IBI362)
LY3305677, IBI362, OXM3
Dual GLP-1/glucagon receptor agonist (LY3305677/IBI362) discovered in 2018, combining GLP-1 and glucagon signaling for stronger metabolic effects than single-receptor drugs. In Phase 3 trials for obesity and type 2 diabetes, showing notable weight loss and glycemic improvement.
Research score 85/100. Reference only, not a dose.
- Appetite Suppression
- Metabolic Enhancement
- Blood Sugar Control
- GLP-1 Agonist
- Weight Loss
- Insulin Regulation
- US status
- Investigational
- Approval
- Phase 3 Clinical Trial
- Evidence
- Investigational GLP-1R and GCGR dual agonist. Shows significant weight loss and glycemic control in Type 2 diabetes and obesity trials.
- Research score
- 85 / 100
- Indication
- Obesity/Weight Management
- Origin
- China
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
GLP-1 receptor activation boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and promotes satiety, while glucagon receptor activation raises energy expenditure and lipid metabolism; structural changes resist DPP-4 breakdown and bind albumin for once-weekly dosing.
Safety file
Mostly mild-to-moderate GI effects (nausea, diarrhea, vomiting), transient; some increased heart rate; low rate of serious adverse events, with no severe hypoglycemia in non-diabetics.
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
- Headache